EVALUATING
Ones to Watch

Ones to Watch

Private ADC-focused company based in Seattle with three early clinical-stage programs including a lead targeting FRα, the same target as ImmunoGen/AbbVie’s Elahere. Claims superior linker technology may allow more potent payload, greater ADC efficacy and lower drug resistance.

www.profoundbio.com

Private, preclinical-stage German ADC company focused on conjugation technologies, with a topoisomerase inhibitor payload platform. Claims superior ADC design with flexible linkers that enable safe and effective use of a wider range of payloads. Multi-target partnership with BMS.

www. tubulis.com

Ones to Watch

Private Dantari’s ADC conjugation platform aims to overcome current ADC limitations with “tunable” release kinetics, higher drug-to-antibody ratios (DAR) to enhance efficacy, and drug-antibody binders that are themselves targeted, to allow multi-specificity. Lead Phase 1 program is a novel targeted drug conjugate (minus antibody), but Dantari has a next-gen ADC in pre-clinical testing. The California-based company raised a $47 million Series A in late 2022 led by Westlake Village Partners.

www.dantari.com

Netherlands-based biotech whose ‘click-to-release’ technology promises to expand the reach of ADCs by opening up a wider range of targets. Lead program is pre-clinical. Tagworks, spun out of Philips Healthcare in 2011, raised a $65 million Series A in June 2023 led by Ysios and Gilde Healthcare.